A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC).
F. Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
T. D. Bachelot
Consultant or Advisory Role - Novartis
Research Funding - Novartis
M. Campone
No relevant relationships to disclose
F. Dalenc
No relevant relationships to disclose
J. M. Perez-Garcia
No relevant relationships to disclose
S. A. Hurvitz
No relevant relationships to disclose
N. C. Turner
Consultant or Advisory Role - Novartis
Honoraria - Novartis
H. S. Rugo
Research Funding - Novartis
J. Baselga
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Y. Zhang
Employment or Leadership Position - Novartis